Caribou Biosciences
Biotech making off-the-shelf CRISPR cell therapies for cancer using its chRDNA platform.
On the record
Checkpoint: Deadline to sign a Phase 3 funding partner for vispa-cel before cash runway runs out
The call
Caribou has real clinical data and regulatory backing but cannot fund its own Phase 3 trial without an outside partner.
Caribou Biosciences uses a gene-editing technique called chRDNA to create cancer-fighting cells that could replace existing CAR-T therapies made by much larger companies like Bristol Myers Squibb, Gilead, and Johnson & Johnson. The science appears real based on early patient data, but the company only has enough money to last into late 2027 and cannot pay for the large final trial needed to prove the drug actually works. The company will almost certainly need a partner to fund that trial within the next year or so. If a partner steps forward, the company has a genuine shot at building something valuable. If no partner appears, the stock could become worthless because the company will run out of cash and the drug will never reach patients.
Why
01
AI pressure: Profluent Bio and other AI-designed gene-editing tool developers. AI-generated Cas enzymes could match or beat Caribou's editing precision without its patent estate. Could AI do the core job? Unlikely.
02
Bigger players: Bristol Myers Squibb, Gilead/Kite, J&J/Legend, Novartis with approved autologous CAR-T therapies. These approved CAR-T products already treat the patients Caribou's off-the-shelf therapy aims to reach. Could a giant copy it? Probably.
03
What protects it. RMAT designation, FDA-aligned Phase 3 design, and real Phase 1 data give it something a partner could still fund.
What would change this call
Caribou announces a signed Phase 3 (ANTLER-3) pharma partnership with upfront funding within 12-18 months. Shows the moat can be monetized before cash runs out in 2H 2027.
Caribou issues equity near $1.50 or discloses a Nasdaq listing-compliance notice. Shows funding distress is forcing dilution or delisting risk before a partner appears.
Longer Phase 1 follow-up data for vispa-cel drops one-year PFS below 51%. Shows the clinical differentiation versus approved CAR-T therapies is eroding.
Caribou issues equity near $1.50 or discloses a Nasdaq listing-compliance notice. Shows funding distress is forcing dilution or delisting risk before a partner appears.
Longer Phase 1 follow-up data for vispa-cel drops one-year PFS below 51%. Shows the clinical differentiation versus approved CAR-T therapies is eroding.
Key numbers
- $118.6M cash, guided to last into 2H 2027
- $148.13M net loss in FY2025
- 92% ORR for CB-011 in Phase 1 cohort
Named risks
- Cash runway guided only into 2H 2027 with explicit inability to fund Phase 3 trial alone.
- No confirmed Phase 3 funding partner for vispa-cel as of mid-2026.
- Stock trading near 52-week lows (~$1.38-$3.54), exposing company to Nasdaq listing-compliance risk.
- No approved product; competing against better-funded allogeneic and entrenched autologous rivals.
- Shareholder governance friction shown by June 18, 2026 vote against officer-exculpation proposal.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| CRISPR Therapeutics | gaining on | Better capitalized rival racing the same allogeneic CAR-T targets as of 2026 |
| Allogene Therapeutics | contesting | TALEN-edited allogeneic CAR-T lead candidate cema-cel competing for LBCL market |
| Precision BioSciences | contesting | ARCUS meganuclease platform, azer-cel, partnered with Imugene, competing space |
| Bristol Myers Squibb, Gilead/Kite, Johnson & Johnson/Legend, Novartis | losing to | Approved, commercially entrenched autologous CAR-T therapies Caribou aims to displace |
| AbbVie | losing to | Ended prior CAR-T collaboration with Caribou in late 2023 |
Questions people ask
- Is Caribou Biosciences profitable in 2026?
- No. Caribou reported a net loss of about $148.13 million for full-year 2025 against revenue of only $11.16 million, up 11.66% from $9.99 million in 2024. The company remains pre-commercial with no approved products, funded mainly by collaboration and licensing revenue, not product sales.
- Will Caribou Biosciences run out of cash?
- Caribou held $118.6 million in cash as of March 31, 2026, down from $142.8 million at year-end 2025, guided to last into 2H 2027. Management has explicitly stated it cannot fund the pivotal vispa-cel Phase 3 trial alone and is seeking a financing or partnership solution.
- Has Caribou Biosciences had layoffs?
- Yes. Caribou cut about 12% of staff (21 positions) in July 2024 ending NK-cell research, then 32% (about 47 employees) in April 2025 when it discontinued its lupus, AML, and preclinical programs. Headcount fell from about 158 in 2023 to 97 by December 31, 2025.
- Who is Caribou Biosciences' biggest competitor?
- In allogeneic CAR-T, Caribou competes with Allogene Therapeutics, CRISPR Therapeutics, and Precision BioSciences, while trying to displace entrenched autologous therapies from Bristol Myers Squibb (Breyanzi), Gilead/Kite (Yescarta), and Johnson & Johnson/Legend (Carvykti), all already FDA-approved and commercialized as of 2026.
- Could AI replace Caribou Biosciences?
- No. Caribou's value comes from wet-lab cell manufacturing, clinical trial execution, and FDA regulatory processes like the March 31, 2026 RMAT designation for CB-011, which are physical and regulated. AI tools only assist peripheral tasks like guide-RNA design, not the core clinical or regulatory work.
- Who owns Caribou Biosciences?
- Caribou Biosciences is a publicly traded company (Nasdaq: CRBU) with no parent company, founded October 28, 2011 by Jennifer Doudna, Rachel Haurwitz, Martin Jinek, and James Berger out of UC Berkeley research. It IPO'd July 23, 2021 raising roughly $304 million at $17 per share.
Timeline
- 2026-06-18Shareholder vote rejected officer-exculpation governance proposal
- 2026-05-07Q1 2026 results: $118.6M cash, FDA alignment reached on ANTLER-3 pivotal trial design
- 2026-03-31FDA granted RMAT designation to CB-011
- 2025-11-03Vispa-cel Phase 1 data shown; company says it cannot fund Phase 3 alone
- 2025-04-2432% workforce cut; lupus, AML (CB-012), and preclinical programs discontinued
- 2024-07-0112% workforce cut (~21 positions); NK-cell research program ended
- 2023-11-01AbbVie halted its CAR-T collaboration with Caribou
- 2021-07-23IPO completed on Nasdaq, raising about $304 million at $17 per share
- 2011-10-28Founded by Jennifer Doudna, Rachel Haurwitz, Martin Jinek, and James Berger
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Caribou Biosciences Inc. Company Profile & Executives - WSJ
- Caribou raises $304M in one of gene editing's most lucrative IPOs (2021-07-23)
- Caribou Biosciences careers on to public markets (2021-11-15)
- Where Are They Now: Caribou Biosciences
- gurufocus.com (2026-07-24)
- Caribou Biosciences (CRBU) Stock Price & Overview (2026-06-17)
- Caribou's CB-010 Shows Clinical Promise and Seeks Partner to Fund Phase 3 (2025-11-03)
- Caribou Biosciences Reports First Quarter 2026 Financial Results (2026-05-07)
- Caribou Biosciences Reports First Quarter 2026 Financial Results (2026)
- Caribou Biosciences (CRBU) Number of Employees (2026-06-17)
- Caribou cuts 32% of staff, further purges cell therapy pipeline (2025-04-24)
- Caribou Changes Course Again, Lays Off 32% of Workforce (2025-04-25)